Cantor Fitzgerald Sticks with Neutral Rating on Merck Amid Ongoing Market Debate

Cantor Fitzgerald has reaffirmed its Neutral rating on Merck & Co. (MRK) stock, setting a price target of $120.00. The firm's analysts pointed to the forthcoming ESMO event as a key factor in their decision, where data from the INTerpath-001 study will be presented.

INTerpath-001 has been making waves due to its early stoppage in adjuvant melanoma treatment, with Cantor Fitzgerald noting that it has already added over $40 billion to Merck's market capitalization. The firm also praised the company's efforts beyond melanoma, giving credit for meaningful contributions.

The stock is currently trading at $149.50, near its 52-week high of $156.92, reflecting a remarkable 91% return over the past year. However, according to InvestingPro analysis, Merck shares appear slightly overvalued relative to their Fair Value.